The role of vorasidenib in the treatment of isocitrate dehydrogenase-mutant glioma.

de la Fuente MI, Touat M, van den Bent MJ, Preusser M, Peters KB, Young RJ, Huang RY, Ellingson BM, Capper D, Phillips JJ, Halasz LM, Shih HA, Rudà R, Lim-Fat MJ, Blumenthal DT, Weller M, Arakawa Y, Whittle JR, Ducray F, Reardon DA, Bi WL, Minniti G, Rahman R, Hervey-Jumper S, Chang SM, Wen PY

Open source

DOI: 10.1093/neuonc/noae259
Published: 2025 Jun 21
Container: Neuro-oncology
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1093/neuonc/noae259,
  title = {The role of vorasidenib in the treatment of isocitrate dehydrogenase-mutant glioma.},
  author = {de la Fuente MI and Touat M and van den Bent MJ and Preusser M and Peters KB and Young RJ and Huang RY and Ellingson BM and Capper D and Phillips JJ and Halasz LM and Shih HA and Rudà R and Lim-Fat MJ and Blumenthal DT and Weller M and Arakawa Y and Whittle JR and Ducray F and Reardon DA and Bi WL and Minniti G and Rahman R and Hervey-Jumper S and Chang SM and Wen PY},
  year = {2025},
  journal = {Neuro-oncology},
  doi = {10.1093/neuonc/noae259},
  url = {https://doi.org/10.1093/neuonc/noae259}
}

RIS

TY  - JOUR
TI  - The role of vorasidenib in the treatment of isocitrate dehydrogenase-mutant glioma.
AU  - de la Fuente MI
AU  - Touat M
AU  - van den Bent MJ
AU  - Preusser M
AU  - Peters KB
AU  - Young RJ
AU  - Huang RY
AU  - Ellingson BM
AU  - Capper D
AU  - Phillips JJ
AU  - Halasz LM
AU  - Shih HA
AU  - Rudà R
AU  - Lim-Fat MJ
AU  - Blumenthal DT
AU  - Weller M
AU  - Arakawa Y
AU  - Whittle JR
AU  - Ducray F
AU  - Reardon DA
AU  - Bi WL
AU  - Minniti G
AU  - Rahman R
AU  - Hervey-Jumper S
AU  - Chang SM
AU  - Wen PY
PY  - 2025
JO  - Neuro-oncology
DO  - 10.1093/neuonc/noae259
UR  - https://doi.org/10.1093/neuonc/noae259
ER  -

APA

MI, D. L. F., M, T., MJ, V. D. B., M, P., KB, P., RJ, Y., RY, H., BM, E., D, C., JJ, P., LM, H., HA, S., R, R., MJ, L., DT, B., M, W., Y, A., JR, W., F, D., DA, R., WL, B., G, M., R, R., S, H., SM, C., & PY, W. (2025). The role of vorasidenib in the treatment of isocitrate dehydrogenase-mutant glioma.. Neuro-oncology. https://doi.org/10.1093/neuonc/noae259

Source records

pubmed · retrieved 2026-09-26T20:37:28.323Z